Apr 12, 2013, 10.26 AM | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Ranbaxy Laboratories.
Sudarshan Sukhani (more)
Technical Analyst, s2analytics.com | Capital Expertise: Equity - Technical
Sukhani told CNBC-TV18, " Ranbaxy Laboratories has a much better chart. It was a v-shaped, went into a hurdle, into a trading range and that trading range should be bought into. It is not making a larger basing pattern. So, unlike Maruti, which still has to make that pattern, but Ranbaxy is suggesting that a strong base is developing and it is on the verge of breaking out from that larger base. Therefore, it is a day trade for the day and it is a positional trade assuming things go wrong with other sectors, pharmaceutical should still continue to be cheerful. It is a nice buying opportunity."
At 09:52 hrs Ranbaxy Laboratories was quoting at Rs 451.45, up Rs 4.05, or 0.91 percent. It has touched an intraday high of Rs 453.70 and an intraday low of Rs 443.10.
Disclosure: Sudarshan Sukhani has no holdings in the stock discussed.
Why US tech giants are buying British AI start-ups
Microsoft announced that it had acquired London-ba
Merrill Lynch buys 19 lakh shares of Vikas Ecotech
On February 5, 2016 Merrill Lynch Capital Markets
RBI to buy back inflation indexed bonds maturing 2023
The not-so-successful bonds have received a tepid
Rallis India buys 19% stake in Metahelix Life for Rs 73.33 cr
Rallis India has acquired additional stake of 19.4
Buy Jagran Prakashan; target of Rs 178: Axis Direct
Axis Direct is bullish on Jagran Prakashan and Fin
Buy Yes Bank; target of Rs 900: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Yes Bank and has
Short DHFL, says Sudarshan Sukhani
Sudarshan Sukhani of s2analytics.com recommends sh
Short Reliance Capital, says Sudarshan Sukhani
Sudarshan Sukhani of s2analytics.com is of the vie